Valneva Submits Label Extension Application to US FDA for Chikungunya Vaccine IXCHIQ

MT Newswires Live11-27

Valneva (VALN) said Tuesday it has submitted a label extension application to the US Food and Drug Administration to expand the use of its chikungunya virus vaccine IXCHIQ to individuals between 12 and 17 years old.

The application also seeks to include two-year antibody persistence data on the product label, highlighting a key differentiator for IXCHIQ, which is currently approved for use in adults, the vaccine maker said.

The label extension application is based on positive phase 3 data from May, showing that a single dose of IXCHIQ produced a "high" and "sustained" immune response in 99.1% of adolescents, with the vaccine being generally well tolerated, Valneva said.

Shares of Valneva were down nearly 6% in recent Tuesday trading.

Price: 4.08, Change: -0.25, Percent Change: -5.77

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2486488977?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-27 01:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2486488977","market":"sg","top_or_hot":-1,"title":"Valneva Submits Label Extension Application to US FDA for Chikungunya Vaccine IXCHIQ","media":"MT Newswires Live","content":"<html><body><p> Valneva (VALN) said Tuesday it has submitted a label extension application to the US Food and Drug Administration to expand the use of its chikungunya virus vaccine IXCHIQ to individuals between 12 and 17 years old.</p><p>The application also seeks to include two-year antibody persistence data on the product label, highlighting a key differentiator for IXCHIQ, which is currently approved for use in adults, the vaccine maker said.</p><p>The label extension application is based on positive phase 3 data from May, showing that a single dose of IXCHIQ produced a \"high\" and \"sustained\" immune response in 99.1% of adolescents, with the vaccine being generally well tolerated, Valneva said.</p><p>Shares of Valneva were down nearly 6% in recent Tuesday trading.</p><p>Price: 4.08, Change: -0.25, Percent Change: -5.77</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Valneva Submits Label Extension Application to US FDA for Chikungunya Vaccine IXCHIQ</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nValneva Submits Label Extension Application to US FDA for Chikungunya Vaccine IXCHIQ\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-27 01:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Valneva (VALN) said Tuesday it has submitted a label extension application to the US Food and Drug Administration to expand the use of its chikungunya virus vaccine IXCHIQ to individuals between 12 ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VALN","symbol_name":"Valneva SE","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2486488977","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2486488977","pubTimestamp":1732642021,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Valneva  said Tuesday it has submitted a label extension application to the US Food and Drug Administration to expand the use of its chikungunya virus vaccine IXCHIQ to individuals between 12 and 17 years old.The application also seeks to include two-year antibody persistence data on the product label, highlighting a key differentiator for IXCHIQ, which is currently approved for use in adults, the vaccine maker said.The label extension application is based on positive phase 3 data from May, showing that a single dose of IXCHIQ produced a \"high\" and \"sustained\" immune response in 99.1% of adolescents, with the vaccine being generally well tolerated, Valneva said.Shares of Valneva were down nearly 6% in recent Tuesday trading.Price: 4.08, Change: -0.25, Percent Change: -5.77","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VALN":"Valneva SE","BK4139":"生物科技","BK4539":"次新股"},"translate_title":"Valneva向美国FDA提交基孔肯雅热疫苗IXCHIQ标签延期申请","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VALN":0.9},"content_text":"Valneva (VALN) said Tuesday it has submitted a label extension application to the US Food and Drug Administration to expand the use of its chikungunya virus vaccine IXCHIQ to individuals between 12 and 17 years old.The application also seeks to include two-year antibody persistence data on the product label, highlighting a key differentiator for IXCHIQ, which is currently approved for use in adults, the vaccine maker said.The label extension application is based on positive phase 3 data from May, showing that a single dose of IXCHIQ produced a \"high\" and \"sustained\" immune response in 99.1% of adolescents, with the vaccine being generally well tolerated, Valneva said.Shares of Valneva were down nearly 6% in recent Tuesday trading.Price: 4.08, Change: -0.25, Percent Change: -5.77","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2486488977"}